Treatment of blastomycosis with higher doses of fluconazole

Peter G. Pappas; Robert W. Bradsher; Carol A. Kauffman; Gretchen A. Cloud; Carolynn J. Thomas; G. Douglas Campbell; Stanley W. Chapman; Cheryl L Newman; William E. Dismukes

doi:10.1086/514539

Treatment of blastomycosis with higher doses of fluconazole

Peter G. Pappas, Robert W. Bradsher, Carol A. Kauffman, Gretchen A. Cloud, Carolynn J. Thomas, G. Douglas Campbell, Stanley W. Chapman, Cheryl L Newman, William E. Dismukes

Research output: Contribution to journal › Article › peer-review

92 Scopus citations

Abstract

Recent clinical data suggest that fluconazole at daily doses of 200 to 400 mg for at least 6 months is moderately effective therapy for non-life- threatening blastomycosis. To examine the usefulness of higher doses of fluconazole therapy for this disorder, we conducted a multicenter, randomized, open-label study to determine the efficacy and safety of two different daily doses of fluconazole (400 and 800 mg) in the treatment of non-life-threatening blastomycosis. Of 39 patients evaluable for efficacy analysis, 34 (87%) were successfully treated, including 89% and 85% of patients who received 400 and 800 mg, respectively. Five (83%) of six patients for whom prior antifungal therapy had failed were successfully treated. The mean duration of therapy was 8.9 months for successfully treated patients. Nineteen patients (48%) reported adverse events, although most were minor. We conclude that fluconazole at daily doses of 400 to 800 mg for at least 6 months is effective therapy for non-life-threatening blastomycosis.

Original language	English (US)
Pages (from-to)	200-205
Number of pages	6
Journal	Clinical Infectious Diseases
Volume	25
Issue number	2
DOIs	https://doi.org/10.1086/514539
State	Published - 1997
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1086/514539

Cite this

@article{d8a8a56e17a947b0a37f2d46327c6964,

title = "Treatment of blastomycosis with higher doses of fluconazole",

abstract = "Recent clinical data suggest that fluconazole at daily doses of 200 to 400 mg for at least 6 months is moderately effective therapy for non-life- threatening blastomycosis. To examine the usefulness of higher doses of fluconazole therapy for this disorder, we conducted a multicenter, randomized, open-label study to determine the efficacy and safety of two different daily doses of fluconazole (400 and 800 mg) in the treatment of non-life-threatening blastomycosis. Of 39 patients evaluable for efficacy analysis, 34 (87%) were successfully treated, including 89% and 85% of patients who received 400 and 800 mg, respectively. Five (83%) of six patients for whom prior antifungal therapy had failed were successfully treated. The mean duration of therapy was 8.9 months for successfully treated patients. Nineteen patients (48%) reported adverse events, although most were minor. We conclude that fluconazole at daily doses of 400 to 800 mg for at least 6 months is effective therapy for non-life-threatening blastomycosis.",

author = "Pappas, {Peter G.} and Bradsher, {Robert W.} and Kauffman, {Carol A.} and Cloud, {Gretchen A.} and Thomas, {Carolynn J.} and Campbell, {G. Douglas} and Chapman, {Stanley W.} and Newman, {Cheryl L} and Dismukes, {William E.}",

note = "Funding Information: Received 23 September 1996; revised 8 January 1997. Informed consent was obtained from the patients, and the guidelines for human experimentation of the U.S. Department of Health and Human Services were followed in the conduct of this study. Financial support: This work was supported in part by the National Institute of Allergy and Infectious Diseases Mycoses Study Group (contract NO1-AI-65296) and Pfizer. * The National Institute of Allergy and Infectious Diseases Mycoses Study Group members who participated in this study are listed at the end of the text. Reprints or correspondence: Dr. Peter G. Pappas, 1900 University Boulevard, 229 Tinsley Harrison Tower, Birmingham, Alabama 35294-0006.",

year = "1997",

doi = "10.1086/514539",

language = "English (US)",

volume = "25",

pages = "200--205",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Treatment of blastomycosis with higher doses of fluconazole

AU - Pappas, Peter G.

AU - Bradsher, Robert W.

AU - Kauffman, Carol A.

AU - Cloud, Gretchen A.

AU - Thomas, Carolynn J.

AU - Campbell, G. Douglas

AU - Chapman, Stanley W.

AU - Newman, Cheryl L

AU - Dismukes, William E.

N1 - Funding Information: Received 23 September 1996; revised 8 January 1997. Informed consent was obtained from the patients, and the guidelines for human experimentation of the U.S. Department of Health and Human Services were followed in the conduct of this study. Financial support: This work was supported in part by the National Institute of Allergy and Infectious Diseases Mycoses Study Group (contract NO1-AI-65296) and Pfizer. * The National Institute of Allergy and Infectious Diseases Mycoses Study Group members who participated in this study are listed at the end of the text. Reprints or correspondence: Dr. Peter G. Pappas, 1900 University Boulevard, 229 Tinsley Harrison Tower, Birmingham, Alabama 35294-0006.

PY - 1997

Y1 - 1997

N2 - Recent clinical data suggest that fluconazole at daily doses of 200 to 400 mg for at least 6 months is moderately effective therapy for non-life- threatening blastomycosis. To examine the usefulness of higher doses of fluconazole therapy for this disorder, we conducted a multicenter, randomized, open-label study to determine the efficacy and safety of two different daily doses of fluconazole (400 and 800 mg) in the treatment of non-life-threatening blastomycosis. Of 39 patients evaluable for efficacy analysis, 34 (87%) were successfully treated, including 89% and 85% of patients who received 400 and 800 mg, respectively. Five (83%) of six patients for whom prior antifungal therapy had failed were successfully treated. The mean duration of therapy was 8.9 months for successfully treated patients. Nineteen patients (48%) reported adverse events, although most were minor. We conclude that fluconazole at daily doses of 400 to 800 mg for at least 6 months is effective therapy for non-life-threatening blastomycosis.

AB - Recent clinical data suggest that fluconazole at daily doses of 200 to 400 mg for at least 6 months is moderately effective therapy for non-life- threatening blastomycosis. To examine the usefulness of higher doses of fluconazole therapy for this disorder, we conducted a multicenter, randomized, open-label study to determine the efficacy and safety of two different daily doses of fluconazole (400 and 800 mg) in the treatment of non-life-threatening blastomycosis. Of 39 patients evaluable for efficacy analysis, 34 (87%) were successfully treated, including 89% and 85% of patients who received 400 and 800 mg, respectively. Five (83%) of six patients for whom prior antifungal therapy had failed were successfully treated. The mean duration of therapy was 8.9 months for successfully treated patients. Nineteen patients (48%) reported adverse events, although most were minor. We conclude that fluconazole at daily doses of 400 to 800 mg for at least 6 months is effective therapy for non-life-threatening blastomycosis.

UR - http://www.scopus.com/inward/record.url?scp=16944362231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16944362231&partnerID=8YFLogxK

U2 - 10.1086/514539

DO - 10.1086/514539

M3 - Article

C2 - 9332510

AN - SCOPUS:16944362231

SN - 1058-4838

VL - 25

SP - 200

EP - 205

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 2

ER -

Treatment of blastomycosis with higher doses of fluconazole

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this